One study raised the concern of increased long term risks for developing myelodysplasia (MDS) and acute myeloid leukemia (AML) in stem cell donors who receive repeated G–CSF dosing for cell mobilization47. The gene discussed is CSF3; the disease is myelodysplastic syndrome.